Coming of Age for the Photoreceptor Synapse.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
02 09 2021
Historique:
entrez: 22 9 2021
pubmed: 23 9 2021
medline: 23 11 2021
Statut: ppublish

Résumé

To discuss the potential contribution of rod and cone synapses to the loss of visual function in retinal injury and disease. The published literature and the authors' own work were reviewed. Retinal detachment is used as a case study of rod spherule and cone pedicle plasticity after injury. Both rod and cone photoreceptors terminals are damaged after detachment although the structural changes observed are only partially overlapping. For second-order neurons, only those associated with rod spherules respond consistently to injury by remodeling. Examination of signaling pathways involved in plasticity of conventional synapses and in neural development has been and may continue to be productive in discovering novel therapeutic targets. Rho kinase (ROCK) inhibition is an example of therapy that may reduce synaptic damage by preserving normal synaptic structure of rod and cone cells. We hypothesize that synaptic damage contributes to poor visual restoration after otherwise successful anatomical repair of retinal detachment. A similar situation may exist for patients with degenerative retinal disease. Thus, synaptic structure and function should be routinely studied, as this information may disclose therapeutic strategies to mitigate visual loss.

Identifiants

pubmed: 34550300
pii: 2777920
doi: 10.1167/iovs.62.12.24
pmc: PMC8475281
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

24

Subventions

Organisme : NEI NIH HHS
ID : R01 EY012031
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY021542
Pays : United States

Références

Invest Ophthalmol Vis Sci. 2013 Aug 28;54(8):5836-47
pubmed: 23908179
Am J Ophthalmol. 2000 Feb;129(2):215-23
pubmed: 10682975
Science. 2001 Nov 2;294(5544):1030-8
pubmed: 11691980
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4177-87
pubmed: 18503000
Am J Pathol. 2012 Jun;180(6):2548-60
pubmed: 22521302
Nat Neurosci. 2014 Sep;17(9):1190-7
pubmed: 25086610
Ir J Med Sci. 2020 Feb;189(1):355-363
pubmed: 31418155
Mol Vis. 2002 Aug 27;8:306-14
pubmed: 12355062
Invest Ophthalmol Vis Sci. 1998 Apr;39(5):808-19
pubmed: 9538889
J Neurosci. 2002 Aug 15;22(16):7065-79
pubmed: 12177203
J Ophthalmic Vis Res. 2013 Oct;8(4):321-9
pubmed: 24653819
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7847-58
pubmed: 26658506
Ophthalmology. 2006 Oct;113(10):1734-42
pubmed: 17011955
Ophthalmology. 1999 Sep;106(9):1811-5; discussion 1816
pubmed: 10485555
Eye Sci. 2013 Sep;28(3):148-52
pubmed: 24579557
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2782-91
pubmed: 17525213
J Neurosci. 1995 Aug;15(8):5429-38
pubmed: 7643192
BMC Ophthalmol. 2014 Aug 22;14:102
pubmed: 25149138
Exp Eye Res. 1999 Jan;68(1):51-7
pubmed: 9986741
Mol Vis. 2000 Nov 03;6:204-15
pubmed: 11063754
Cold Spring Harb Perspect Biol. 2010 Apr;2(4):a001842
pubmed: 20452946
Cell Rep. 2019 May 14;27(7):2171-2183.e5
pubmed: 31091454
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3892-906
pubmed: 27472075
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):967-73
pubmed: 15728554
Prog Retin Eye Res. 2003 Sep;22(5):607-55
pubmed: 12892644
Am J Pathol. 2006 Jan;168(1):331-9
pubmed: 16400034
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):11
pubmed: 32176262
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):42
pubmed: 32343782
Cold Spring Harb Perspect Biol. 2011 Jun 01;3(6):
pubmed: 21123392
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):991-1001
pubmed: 19815726
J Neurosci. 2005 Mar 9;25(10):2761-70
pubmed: 15758186
Blood. 2011 Jun 2;117(22):6024-35
pubmed: 21355092
Dev Dyn. 2010 Jun;239(6):1695-707
pubmed: 20503366
J Comp Neurol. 1999 Dec 6;415(1):1-16
pubmed: 10540354
Invest Ophthalmol Vis Sci. 1998 Mar;39(3):618-30
pubmed: 9501874
Prog Retin Eye Res. 2005 May;24(3):395-431
pubmed: 15708835
Trans Am Ophthalmol Soc. 1982;80:475-97
pubmed: 6763802
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8222-31
pubmed: 23150628
Br J Ophthalmol. 2007 Sep;91(9):1219-24
pubmed: 17301119
J Neurosci. 2001 Apr 1;21(7):2215-23
pubmed: 11264297
Transl Vis Sci Technol. 2017 Jun 20;6(3):22
pubmed: 28660097
Surv Ophthalmol. 2013 Jul-Aug;58(4):321-9
pubmed: 23642514
Mol Vis. 2009;15:10-25
pubmed: 19137070
Proc R Soc Lond B Biol Sci. 1966 Nov 15;166(1002):80-111
pubmed: 4382694
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1234-47
pubmed: 11923271
Invest Ophthalmol Vis Sci. 2012 Apr 18;53(4):1990-8
pubmed: 22408005
Br J Ophthalmol. 2001 Apr;85(4):410-3
pubmed: 11264128
Glia. 2015 Feb;63(2):216-28
pubmed: 25130721
Mol Brain. 2014 Aug 13;7:53
pubmed: 25116810
Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):73-86
pubmed: 18815803
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3385-3393
pubmed: 30025078
Science. 1974 Nov 1;186(4162):449-51
pubmed: 4369896
Exp Eye Res. 2003 Apr;76(4):463-71
pubmed: 12634111
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3677-86
pubmed: 18660429
Trans Am Ophthalmol Soc. 1988;86:291-306
pubmed: 2979019
Am J Ophthalmol. 1981 Nov;92(5):611-20
pubmed: 7304687
Eur J Neurosci. 2005 Sep;22(5):1057-72
pubmed: 16176347
Curr Mol Med. 2014 Feb;14(2):199-208
pubmed: 24467208
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4318–4331
pubmed: 28806446
Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12156-60
pubmed: 16880381
Invest Ophthalmol Vis Sci. 2011 Feb 01;52(1):579-87
pubmed: 20861490
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3234-41
pubmed: 16877386
Cell Metab. 2013 Oct 1;18(4):505-18
pubmed: 24093675
Eur J Neurosci. 2007 Nov;26(9):2506-15
pubmed: 17970721
Retina. 2007 Mar;27(3):358-64
pubmed: 17460592
Invest Ophthalmol Vis Sci. 2012 Sep 19;53(10):6355-69
pubmed: 22899763
J Comp Neurol. 2007 Jan 10;500(2):286-98
pubmed: 17111373
J Biol Chem. 2002 Dec 20;277(51):49799-807
pubmed: 12376549
Doc Ophthalmol. 2008 Sep;117(2):103-9
pubmed: 18188628
Nature. 2000 Apr 6;404(6778):567-73
pubmed: 10766232
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2274-2285
pubmed: 31112612
Graefes Arch Clin Exp Ophthalmol. 2003 Aug;241(8):673-81
pubmed: 12827374
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5567-81
pubmed: 18055806
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3985-95
pubmed: 19255154
Sci Rep. 2021 Jan 12;11(1):692
pubmed: 33436892
Am J Ophthalmol. 2010 Aug;150(2):205-210.e2
pubmed: 20541738
Invest Ophthalmol Vis Sci. 1983 Jul;24(7):927-42
pubmed: 6862796
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5655-60
pubmed: 11943854
Invest Ophthalmol Vis Sci. 2011 Mar 25;52(3):1693-708
pubmed: 21071736
Synapse. 2013 Aug;67(8):515-31
pubmed: 23592324
Retina. 2010 Jan;30(1):152-9
pubmed: 19940806
Ophthalmologica. 2011;226(2):37-44
pubmed: 21508652
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4976-88
pubmed: 14578425
Mol Vis. 2002 Apr 16;8:114-8
pubmed: 11979236
Invest Ophthalmol Vis Sci. 1998 Feb;39(2):424-34
pubmed: 9478003
Front Neurosci. 2019 Sep 19;13:991
pubmed: 31607844

Auteurs

Ellen Townes-Anderson (E)

Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School, Newark, New Jersey, United States.

Eva Halasz (E)

Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School, Newark, New Jersey, United States.

Weiwei Wang (W)

Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard University, Boston, Massachusetts, United States.

Marco Zarbin (M)

Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH